CoChat

Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma

Hahn, Andrew W., Froerer, Camryn, VanAlstine, Sidney, Rathi, Nityam, Bailey, Erin B., Stenehjem, David D., Agarwal, Neeraj · 2018 · Clinical Genitourinary Cancer
Cited by 46

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Micro‐Abstract Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) are a mainstay of treatment for metastatic renal‐cell carcinoma. Stool microbiome composition is predictive of response to immunotherapy and cytotoxic chemotherapy. Antibiotics targeting Bacteroides species are associated with improved progression‐free survival while receiving first‐line VEGF‐TKIs. Background Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for metastatic renal‐cell carcinoma. Stool microbiome composition is predictive of response to immunotherapy and cytotoxic chemotherapy. We sought to investigate whether antibiotics targeting Bacteroides species affect progression‐free survival (PFS) while receiving first‐line VEGF‐TKI therapy. Patients and Methods Using a retrospective cohort of intermediate‐ and poor‐risk metastatic renal‐cell carcinoma patients from the University of Utah, we categorized patients receiving first‐line VEGF‐TKIs by receipt of antibiotics (Bacteroides spp., non‐Bacteroides spp., or none) and assessed PFS by Kaplan‐Meier and Cox proportional hazard models. Results Of 145 patients, 17 received antibiotics with Bacteroides spp. coverage and 32 patients received antibiotics without Bacteroides spp. coverage. When compared to patients not receiving antibiotics, improved PFS was seen with each additional day antibiotics were prescribed with Bacteroides spp. coverage (hazard ratio = 0.92; 95% confidence interval, 0.83‐0.99; P = .04). Conclusion Targeting stool Bacteroides spp. with antibiotics improves PFS in patients receiving first‐line VEGF‐TKIs in a duration‐dependent manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clgc.2018.05.001

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 46

Metadata

Authors
Hahn, A. W., Froerer, C., VanAlstine, S., Rathi, N., Bailey, E. B., Stenehjem, D. D., & Agarwal, N.
Venue
Clinical Genitourinary Cancer
Publisher
Elsevier BV
Published
2018-10
Volume
16
Issue
5
Pages
365-368
ISSN
1558-7673 (ISSN-L)
OpenAlex
W2807579097
Cited by
46
References
7
FWCI
3.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. https://app.cochat.ai/papers/10.1016/j.clgc.2018.05.001
The paper
Hahn, A. W., Froerer, C., VanAlstine, S., Rathi, N., Bailey, E. B., Stenehjem, D. D., & Agarwal, N. (2018). Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2018.05.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.